Table 5.

Subgroup analysis of correlation between mRSS and pulmonary function by autoantibody profile or disease duration

	Univariate analysis		Multivariate analysis
	N	β (95% CI)	N	β (95% CI)
%FVC
Autoantibody profile
Anti-topo I Ab	65	− 0.68* (− 1.25 to − 0.11)	65	− 0.80** (− 1.39 to − 0.20)
Anti-centromere Ab	60	− 1.36 (− 1.18 to 0.91)
Anti-RNA polymerase III Ab	17	0.66 (− 0.29 to 1.61)
Anti-U1RNP Ab	19	− 0.09 (− 1.07 to 0.89)
Disease duration
< 5 years	106	− 0.41* (− 0.77 to − 0.05)	106	− 0.43* (− 0.84 to − 0.02)
≥ 5 years	69	− 1.53*** (− 2.36 to − 0.70)	69	− 1.48** (− 2.33 to − 0.63)
%DLco
Autoantibody profile
Anti-topo I Ab	62	− 0.80** (− 1.36 to − 0.24)	53	− 0.68* (− 1.27 to − 0.08)
Anti-centromere Ab	58	− 0.02 (− 1.02 to 1.07)
Anti-RNA polymerase III Ab	17	− 0.07 (− 1.03 to 0.89)
Anti-U1RNP Ab	19	− 0.63 (− 1.59 to 0.32)
Disease duration
< 5 years	104	− 0.70** (− 1.10 to − 0.30)	104	− 0.52* (− 0.97 to − 0.07)
≥ 5 years	66	− 0.86* (− 1.61 to − 0.11)	66	− 0.68 (− 1.43 to 0.06)

N number of the observation, β regression coefficient, CI confidence interval. Asterisk (*) indicates statistical significance in regression analysis.*P < 0.05; **P < 0.01; ***P < 0.001